Document:

EX-4.19 AGREEMENT - BEACON CAPITAL PARTNERS, LLP

                                  CONFIDENTIAL AGREEMENT

  This agreement ("Agreement") describes the transaction (the "Transaction")
between Consygen Inc. ("Consygen" or the "Company") and Beacon Capital Partners,
LLP ("Beacon") whereby Consygen will issue to Beacon authorized and as-yet
unregistered common stock in the amount of One Million Dollars ($1,000,000) at
the agreed-to price of $0.09 per share, for a total of 11,111,111 common shares
(the "Shares").

  Beacon agrees that it will make weekly payments to Consygen at the
above-stated price per share until the earlier of (a) all of Shares have been
purchased and funds issued to Consygen; or (b) thirty-five (35) days after the
execution of this Agreement (the "Maturity Date"). In the event that all of the
shares have not been purchased at the Maturity Date, Consygen has the sole right
to take back all unsold shares or extend the Agreement for an additional twenty
(20) days. The first payment on the Shares shall occur no later than one (1)
week following execution of this Agreement.

  In exchange for delivery of the Shares to Beacon, Beacon shall execute a
promissory note in the amount of One Million Dollars ($1,000,000) with Consygen
as the payee (the "Note"). The Note will mature on the Maturity Date (unless
extended by Consygen as described above). Upon maturity, if Consygen elects not
to extend the Transaction as described above, Beacon shall return all of the
unsold Shares to Consygen. Accounting at the Maturity Date for all cash and
unsold Shares returned to Consygen shall total $1,000,000, in which case the
Note shall expire and be declared null and void, with Beacon having no further
obligation.

  Consygen hereby agrees to include the Shares in its current registration
statement, and further agrees that should the Shares not be included in the
current registration statement, Beacon (and any other holders of the Shares)
will be grievously harmed. Therefore, Consygen agrees that if these Shares are
not included in the current registration statement, and, if these shares do not
become free-trading by February 15, 2001, then Consygen will be fined an
additional 200,000 penalty shares per month until such time as the shares are
registered.

  At the Maturity Date, (or completion of the Transaction, if earlier), Beacon
will have the right to appoint up to two (2) members of the Company's board of
directors mutually satisfactory to Consygen (such acceptance not to be
unreasonably withheld).

  The laws of the State of Arizona shall govern this Agreement.

  This Agreement shall be declared effective upon execution by authorized
officers of the parties and dated as of the date below.

AGREED AND ACCEPTED

BEACON CAPITAL PARTNERS, LLP                     CONSYGEN INC.

/s/Scott Miller                                  /s/Eric J. Strasser
-------------------                              --------------------
Authorized Officer                               Authorized Officer

Date:  12/18/00                                  Date: 12/20/00EX-4.20 AGREEMENT - SURRENDER OF STOCK OPTIONS - EMPLOYEES

                                                              September 11, 2001

         The undersigned is the holder of options to purchase _________________
shares of common stock ("Options") of ConSyGen, Inc. (the "Company"). The
agreement(s) evidencing the Options are hereby amended to (i) reduce the
exercise price to $_____ per share, (ii) increase option shares to purchase to
_______________, and (iii) provide that the Options shall not be exercisable
until such time as the Company increases to at least 125,000,000 the number of
its authorized but unissued shares of common stock and completes an S-8
registration.

         In the event the employee is laid off by CSGI prior to the increase in
the authorized shares becoming effective, the employee will have nine months
from the day the increase becomes effective to exercise their options.

         Please indicate your agreement with the foregoing by countersigning
this letter where indicated below and returning a copy to the undersigned.
Except as modified hereby, the agreement(s) evidencing Options shall remain in
full force and effect.

                                             Sincerely,

                                             By: _______________________________

ACCEPTED AND AGREED:
ConSyGen, Inc.

By:  ____________________________________
     Eric J. Strasser, Chief Financial OfficerEX-4.21 AGREEMENT - SURRENDER OF SHARES/STOCK OPTIONS/WARRANTS - INVESTORS

                                                              September 13, 2001
ConSyGen, Inc.
125 South 52nd Street
Tempe, AZ 85281
Attn:  Eric Strasser, CFO

         Re:      Deferral of Share Issuance

Ladies and Gentlemen:

As of September 13, 2001, the undersigned holds an aggregate of ____________
shares of common stock (the "Shares") of ConSyGen, Inc. (the "Company"), which
the undersigned has agreed to surrender to the Company. The undersigned
understands that the Company does not currently have sufficient authorized but
unissued shares of common stock to execute its business and financial plans. In
consideration of the foregoing and other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, the undersigned does
hereby waive his right to receive the shares until such time as the Company
increases to at least 125,000,000 the number of the Company's authorized shares
of common stock. Following such increase, the Company shall have the option to
either (i) issue the undersigned ____________ shares of its common stock, or
(ii) pay the undersigned an aggregate of $_________, in lieu of issuing such
shares to the undersigned. The Company shall use its best efforts to cause the
number of its authorized shares of common stock to be increased to at least
125,000,000 within ninety (90) days of the date hereof.

                                                   Sincerely,

                                                   [Name]

AGREED AND ACCEPTED:

ConSyGen, Inc.

By:
      Name:    Robert Reisch
      Title:   Chief Executive Officer,
               duly authorized

By:
      Name:    Eric Strasser
      Title:   Chief Financial Officer,
               duly authorized
<PAGE>
                                                              September 13, 2001
ConSyGen, Inc.
125 South 52nd Street
Tempe, AZ 85281
Attn:  Eric Strasser, CFO

         Re:      Deferral of Share Issuance

Ladies and Gentlemen:

As of September 13, 2001, the undersigned is entitled to an option for an
aggregate of _________ shares of common stock (the "Options") of ConSyGen, Inc.
(the "Company"). The undersigned understands that the Company does not currently
have sufficient authorized but unissued shares of common stock to execute its
business and financial plans. In consideration of the foregoing and other good
and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the undersigned does hereby waive his right to exercise the
options until such time as the Company increases to at least 125,000,000 the
number of the Company's authorized shares of common stock. Following such
increase, the Company shall issue to the undersigned an option for _________
shares of its common stock at an exercise price of $0.50 per share. The Company
shall use its best efforts to cause the number of its authorized shares of
common stock to be increased to at least 125,000,000 within ninety (90) days of
the date hereof.

                                                   Sincerely,

                                                   [Name]

AGREED AND ACCEPTED:

ConSyGen, Inc.

By:
      Name:    Robert Reisch
      Title:   Chief Executive Officer,
               duly authorized

By:
      Name:    Eric Strasser
      Title:   Chief Financial Officer,
               duly authorized
<PAGE>
                                                              September 13, 2001

ConSyGen, Inc.
125 South 52nd Street
Tempe, AZ 85281
Attn:  Eric Strasser, CFO

         Re:      Deferral of Share Issuance

Ladies and Gentlemen:

As of September 13, 2001, the undersigned is entitled to an option for an
aggregate of ___________ warrants of common stock (the "Warrants") of ConSyGen,
Inc. (the "Company"). The undersigned understands that the Company does not
currently have sufficient authorized but unissued shares of common stock to
execute its business and financial plans. In consideration of the foregoing and
other good and valuable consideration, the receipt and sufficiency of which are
hereby acknowledged, the undersigned does hereby waive his right to exercise the
warrants until such time as the Company increases to at least 125,000,000 the
number of the Company's authorized shares of common stock. Following such
increase, the Company shall issue to the undersigned a warrant for __________
shares of its common stock at an exercise price of $0.25 per share. The Company
shall use its best efforts to cause the number of its authorized shares of
common stock to be increased to at least 125,000,000 within ninety (90) days of
the date hereof.

                                                   Sincerely,

                                                   [Name]

AGREED AND ACCEPTED:

ConSyGen, Inc.

By:
      Name:    Robert Reisch
      Title:   Chief Executive Officer,
               duly authorized

By:
      Name:    Eric Strasser
      Title:   Chief Financial Officer,
               duly authorizedPrepared by MERRILL CORPORATION

EXHIBIT 4.36

EXECUTION COPY

THIRD FORBEARANCE AGREEMENT

THIS THIRD FORBEARANCE AGREEMENT (this “Agreement”)

is entered into as of September 28, 2001 among LEINER HEALTH PRODUCTS INC.

(the “U.S. Borrower”), VITA HEALTH PRODUCTS INC. (the “Canadian

Borrower,” and together with the U.S. Borrower, the “Borrowers”),

THE BANK OF NOVA SCOTIA, as U.S. Agent and as Canadian Agent, and the lenders

party to the Credit Agreement referred to below.

RECITALS

A.            Pursuant

to that certain Amended and Restated Credit Agreement, dated as of May 15,

1998 (as further amended, supplemented, amended and restated or otherwise

modified prior to the date hereof, the “Credit Agreement”; capitalized

terms used but not defined herein shall have the meanings given them in the

Credit Agreement), the Agents and the Lenders made Loans and other financial

accommodations to the Borrowers.

B.            The

following Defaults or Events of Default (the “Existing Defaults”) exist

under the Credit Agreement:

1.             The failure of the Borrowers to comply with each of the

financial covenants set forth in Section 9.2.4 of the Credit Agreement as

of or for the Fiscal Quarters ending December 31, 2000, March 31,

2001, June 30, 2001 and September 30, 2001; and

2.             The Borrowers’ breach of the representations, warranties

and statements contained in the Loan Documents in connection therewith.

C.            On

or about June 29, 2001, the Borrowers, the Agents and the Lenders entered

into a forbearance agreement (the “First Forbearance Agreement”) pursuant to

which the Agents and the Lenders agreed to forbear with respect to their rights

or remedies against the Borrowers based on the Existing Defaults until

September 1, 2001 and agreed that the forbearance period would be

automatically extended if the Borrowers met certain conditions set forth in

Section 1(b) of the First Forbearance Agreement.

D.            On

or about August 31, 2001, the Borrowers, the Agents and the Lenders

entered into a second forbearance agreement (the “Second Forbearance

Agreement”) pursuant to which the Agents and the Lenders agreed to extend

the Forbearance Period (as defined in the First Forbearance Agreement) until

September 28, 2001.

D.            The

Borrowers, the Agents and the Lenders are continuing to discuss the terms of a

restructuring of the Borrowers’ indebtedness and liabilities, and the Borrowers

have requested that the Required Lenders extend their forbearance on the terms

and conditions set forth below.

E.             The

Required Lenders are willing to forbear from exercising their rights and

remedies in connection with the Existing Defaults on the terms and conditions

set forth herein.

AGREEMENT

In consideration of the

Recitals and of the mutual promises and covenants contained herein, the

Borrowers, the Agents and the Required Lenders agree as follows:

Section

1.  Agreement to Forbear.

(a)           Forbearance.  During the period (the “Forbearance Period”) commencing on

the date hereof and ending on the earlier to occur of November 2, 2001 and

the date of any Forbearance Default (as defined below), and subject to the

satisfaction of the conditions set forth in Section 2 hereof, the Agents

and the Lenders will forbear from exercising their rights and remedies under

the Credit Agreement and the other Loan Documents solely with respect to the

Existing Defaults.  “Forbearance

Default” shall mean: (i) an Event of Default (other than the Existing

Defaults), (ii) the failure of either Borrower to keep or perform any of

the covenants or agreements contained herein providing for a payment or

prepayment to the Agents or the Lenders, (iii) the failure of either

Borrower to keep or perform any of the covenants or agreements contained herein

(other than those referred to in clause (ii) above) two Business Days

after the date the Borrowers receive written notice from an Agent of any such

failure (the “Notice Period”), provided that in the event any

such failure is remedied within the Notice Period, such failure shall not

constitute a Forbearance Default, (iv) any representation or warranty of

either Borrower herein shall be incorrect when made or deemed made in any

material respect, (v) negotiations between the Borrower and the potential

equity investor in the Borrower terminate without the issuance of a commitment

letter or (vi) negotiations between the U.S. Borrower and the

Subordinated Note Holders terminate without agreement on a term sheet for the

treatment of the Subordinated Notes.

(b)           Nature of the Forbearance.  The forbearance set forth herein is limited

and shall not be deemed (i) a waiver of any Default or Event of Default,

including the Existing Defaults, which now exist or may hereafter arise, (ii) a

forbearance with respect to any term, condition or obligation of the Borrowers

in the Credit Agreement or any other Loan Document other than the Existing

Defaults, (iii) a waiver of any of the conditions precedent to Credit

Extensions contained in Section 7.2 of the Credit Agreement or

(iv) subject to the terms contained herein, to prejudice any right or

remedy which any Agent or any Lender may now or in the future have under or in

connection with the Credit Agreement or any other Loan Document.

Section

2.  Conditions Precedent to

Effectiveness of Agreement.  This

Agreement shall not be effective unless and until each of the following

conditions shall have been satisfied in the sole discretion of the Agents:

(a)           The

Agents shall have received (i) counterparts of this Agreement duly

executed by each of the Borrowers and the Required Lenders and (ii) an

Affirmation and Consent, in form and substance satisfactory to the Agents, duly

executed by each of the Guarantors.

(b)           The

Agents shall have received, for the pro rata benefit of the Lenders executing

this Agreement on or before October 5, 2001 (the “Consenting Lenders”),

a forbearance fee of $150,000, which shall be fully earned when paid and nonrefundable.

(c)           The

Agents shall have been reimbursed for the unpaid fees and expenses incurred

through the date hereof of its professionals, including the unpaid fees and

expenses of Luskin, Stern & Eisler LLP, PricewaterhouseCoopers LLP, Casas,

Benjamin & White, LLC (“CBW”) and Hunton & Williams.

(d)           The

Borrowers shall have paid in cash to Luskin, Stern & Eisler LLP, counsel to

the Agents, a retainer in the amount of $75,000.

Section

3.  Representations and Warranties. 

The Borrowers hereby represent and warrant to the Agents and to the

Lenders as follows:

(a)           Recitals.  The Recitals in this Agreement are true and correct in all

respects.

(b)           Incorporation of Representations and Statements.  All statements of the Borrowers contained in

Section 7.2.1 of the Credit Agreement, and all representations and

warranties of the Borrowers in the Credit Agreement and the other Loan

Documents, are incorporated herein in full by this reference and are, other

than with respect to the Existing Defaults, true and correct as of the date

hereof in all material respects.

(c)           Power; Authorization.  Each of the Borrowers has the corporate

power, and has been duly authorized by all requisite corporate action, to

execute and deliver this Agreement and to perform its obligations

hereunder.  This Agreement has been duly

executed and delivered by the Borrowers.

(d)           Enforceability.  This Agreement is the legal, valid and

binding obligation of each of the Borrowers, enforceable against them in

accordance with its terms.

(e)           No Violation.  The execution, delivery and performance of this Agreement does

not and will not (i) violate any law, rule, regulation or court order to which

either of the Borrowers is subject, (ii) conflict with or result in a breach of

any Organic Document of the Borrowers or any agreement or instrument to which

either of the Borrowers is party or by which it or its properties are bound, or

(iii) result in the creation or imposition of any Lien, security interest or

encumbrance on any property of either of the Borrowers, whether now owned or

hereafter acquired, other than liens in favor of the Agents.

(f)            Obligations.  As of the date hereof the outstanding principal balance of the

U.S. Revolving Loans is $90,867,415.83; U.S. Letter of Credit Outstandings is

$11,902,372 (of which $1,600,000 is cash collateralized under the terms of a

Cash Collateral Agreement dated as of April 16, 2001); Term B Loans is

$65,125,196.41; Term C Loans is $62,274,581.93; Term D Loans is

$29,254,342.26; Canadian Revolving Loans is Cdn.$28,739,529.87; Canadian

Swingline Loans is Cdn.$230,000; and Canadian Term Loans is

Cdn.$16,544,824.21.  Interest and fees

have accrued thereon as provided in the Credit Agreement and the other Loan

Documents.  The obligation of the

Borrowers to repay the Loans, together with all interest and fees accrued

thereon, and the other Obligations is absolute and unconditional, and there

exists no right of set off or recoupment, counterclaim or defense of any nature

whatsoever to payment of the Obligations.

Section 4.  Covenants

of Borrowers.  The Borrowers agree as follows:

(a)           Forecasts.  By no later than 4:00 p.m. on the second

Business Day of each week, the Borrowers will deliver to the Agents updated

weekly rolling cash flow forecasts for the following twelve week period,

together with an actual to forecast variance analysis for the preceding week,

which forecasts shall also include a certification from an Authorized Officer

of the U.S. Borrower representing to the information required pursuant to

paragraph (c) below.

(b)           U.S. Balance Sheets.  Within 30 days after the end of each month,

the Borrowers will deliver to the Agents consolidated and consolidating balance

sheets of the U.S. Borrower and its Subsidiaries (including consolidating

balance sheets of the Canadian Borrower and its Subsidiaries) as of the end of

such month, and consolidated and consolidating statements of earnings and cash

flow of the U.S. Borrower and its Subsidiaries (including consolidating

statements of earnings and cash flow of the Canadian Borrower and its

Subsidiaries) for such month and for the period commencing at the end of the

previous Fiscal Year and ending with the last day of such month.

(c)           Disbursements, etc.  The Borrowers will not permit cumulative

(from September 1, 2001) disbursements for all applicable months, as set forth

in the Borrowers’ September 18, 2001 rolling 13-week forecast, as may be

revised with the approval of CBW (the “Forecast”), to exceed 110% of the

cumulative (from September 1, 2001) amounts set forth therefor in the Forecast

and will not permit the cash balance at the end of any month to be less than

90% of the cash balance set forth in the Forecast for such month.  The Borrowers agree that all payments or

disbursements to an Affiliate or employee of a Borrower (including Severance

Payments (as defined below)) inconsistent with the Forecast or which are

otherwise outside of the ordinary course of business must be approved in

advance by David Coles.

(d)           Cooperation.  The Borrowers agree to cooperate fully with the Agents, the

Lenders and their professionals, including in connection with any audit or

appraisal of the business, assets or financial condition of the Borrowers and

their Subsidiaries, in all cases at the Borrowers’ expense.  In addition, the Borrowers agree to deliver

to the Agents on or before October 10, 2001, the final estimated fiscal year

2002 forecast.

(e)           Payment of Fees.  In addition to and not in limitation of the

terms of Section 12.3 of the Credit Agreement, the Borrowers agree to pay

on demand all reasonable fees and expenses of (i) the Agents and all

professionals retained by the Agents or by Luskin, Stern & Eisler LLP

(including special counsel engaged to review various litigation issues), and

(ii) each Lender (other than the legal fees of each Lender expressly

excepted from payment under Section 12.3 of the Credit Agreement), in each

case incurred in connection with the Credit Agreement or this Agreement and the

matters contemplated hereby and the restructuring of the Obligations, and

whether incurred prior to or subsequent to the date hereof.

(f)            Bank Accounts.  Neither the Borrowers nor any of their

Subsidiaries will maintain any checking, savings or other account at any bank

or other financial institution, or any other account where money or securities

may be deposited or maintained, other than the accounts specified in the

Amended and Restated Perfection Certificate dated as of June 15, 2001 and

the Control Agreement and First Amendment to Concentration Bank Agreement, dated

as of August 20, 2001.

(g)           Suspension of Commitments.  The Commitments are suspended, except that

within 10 Business Days of the date hereof, the U.S. Borrower shall deliver a

U.S Issuance Request to the U.S Issuer, and the U.S. Issuer may (in its sole

discretion) issue a U.S. Letter of Credit with respect thereto in a stated

amount of not more than $100,000, the beneficiary of which shall be American

Express, in its capacity as the U.S. Borrower’s corporate travel vendor (or

another corporate travel vendor to the U.S. Borrower), provided that

contemporaneously with such issuance, the U.S Borrower shall permanently repay

U.S. Revolving Loans to the U.S. Agent for the pro rata benefit of the U.S.

Lenders in an amount not less than the stated amount of such U.S. Letter of

Credit.

(h)           LIBOR Restrictions.  The outstanding principal amount of the

Loans may not be continued as, or converted into, LIBO Rate Loans or Canadian

BAs, as applicable.

(i)            Increased Interest.  The Applicable Margin shall in each case be

maintained at a rate of 1% over that otherwise in effect in accordance with the

terms of the Credit Agreement.

(j)            Restrictions on Indebtedness, Etc.  The Borrowers and their Subsidiaries are

prohibited from incurring Indebtedness under clauses (d), (g), (h) or (l)

of Section 9.2.2 of the Credit Agreement; making Investments under

clauses (f), (i) or (j) of Section 9.2.5 of the Credit Agreement;

redeeming shares of Capital Stock under clause (iii) of the proviso to

Section 9.2.6 of the Credit Agreement; consummating acquisitions or

mergers under clauses (b), (c) or (d) of Section 9.2.10 of the Credit

Agreement; or paying any fees under clause (b) of Section 9.2.13 of

the Credit Agreement.

(k)           Monthly Payment of Interest and Fees.  All interest for Base Rate Loans and

Canadian Prime Rate Loans, and all Letter of Credit fees payable under

Section 5.3.3 of the Credit Agreement, shall be payable in arrears on the

fifteenth day of each month (instead of the Quarterly Payment Dates).

(l)            Canadian Balance Sheets.  Within 21 days after the end of each month,

the Canadian Borrower will deliver to the Canadian Agent consolidated and

consolidating balance sheets of the Canadian Borrower and its Subsidiaries as

of the end of such month and consolidated statements of earnings and cash flow

of the Canadian Borrower and its Subsidiaries for such month and for the period

commencing at the end of the previous Fiscal Year and ending with the last day

of such month.

(m)          Intercompany Dispositions.  The U.S. Borrower and its U.S. Subsidiaries

will not, directly or indirectly, make any Investments (including intercompany

loans or capital contributions) in or to the Canadian Borrower or any of the

Canadian Borrower’s Subsidiaries, or sell, transfer, lease, contribute or

otherwise convey (including by way of merger), or grant options, warrants or

other rights (all collectively referred to as a “Disposition”) with

respect to all or any part of their assets to the Canadian Borrower or any of

the Canadian Borrower’s Subsidiaries other than in the ordinary course of

business consistent with past practices. 

The Canadian Borrower and its Subsidiaries will not, directly or

indirectly, make any Investments (including intercompany loans or capital contributions)

in or to (or pay dividends or make distributions to) the U.S. Borrower or any

of the U.S. Borrower’s U.S. Subsidiaries, or make any Disposition with respect

to all or any part of their assets to the U.S. Borrower or any of the U.S.

Borrower’s U.S. Subsidiaries, other than in the ordinary course of business

consistent with past practices.

(n)           Restrictions on Reallocation of Commitments.  The Borrowers’ right to reallocate the

unused Canadian Revolving Loan Commitment Amount and the unused U.S. Revolving

Loan Commitment Amount pursuant to, respectively, Sections 2.2.3 and 3.2.2

of the Credit Agreement is suspended.

(o)           Antitrust Proceeds.  Unless otherwise agreed to by the Required

Lenders, including as to amount and application, concurrently with the receipt

by either of the Borrowers or any of their Affiliates of any judgment,

settlement or other proceeds or amounts, however characterized (with all of the

foregoing collectively referred to as the “Proceeds”), arising from or

in connection with any antitrust claims (the “Claims”) (including claims

pending in (i) the United States District Court for the Central District

of California styled Leiner Health Products Inc. v. F. Hoffman-LaRoche Ltd.,

et al., Case No. 99-09832-JSL and (ii) the United States District

Court for the District of Columbia entitled In Re Vitamins Antitrust

Litigation, MDL No. 1285, Misc. No. 99-0197, and all facts and

circumstances at issue therein), the U.S. Borrower shall make, or cause to be

made, a mandatory prepayment of the Loans in the amount of such Proceeds (with

such prepayment being applied to the remaining Term Loan amortization payments pro

rata in accordance with the amount of each such remaining Term Loan

amortization payment) and the cash collateralization of all Letters of Credit

and a corresponding reduction of each Revolving Loan Commitment Amount.  The Borrowers reaffirm and ratify the

perfected security interest in the Claims and Proceeds of the Agents and the

Lenders.

(p)           Restructuring.  The Borrowers will report to the Agents on a

weekly basis with respect to the status of their negotiations with the

potential equity investor in the Borrowers and the Subordinated Note

Holders.  The Borrowers agree to

continue to negotiate a restructuring of their indebtedness and liabilities in

good faith with the Agents and the Lenders.

(q)           Chief Operating Officer and Chief Financial Officer.  (i) The U.S. Borrower agrees to hire a chief

operating officer of the U.S. Borrower (the “COO”) who shall be

reasonably satisfactory to the Agents and use good faith efforts to complete

such hiring on or before October 15, 2001.  The Borrowers shall provide the Agents and CBW with access to the

executive search firm retained in connection with the COO search process and

will direct such firm to fully cooperate with the Agents and CBW regarding all

reasonable requests for information or documentation in connection

therewith.  The Borrowers will continue

to work in good faith with the Agents and their professionals to refine the

description of the required qualifications, capabilities, role and authority of

the COO position.

(ii) The U.S. Borrower

agrees to hire a chief financial officer of the U.S. Borrower (the “CFO”)

who shall be reasonably satisfactory to the Agents and use good faith efforts

to complete such hiring on or before December 31, 2001.  The Borrowers shall provide the Agents and

CBW with access to the executive search firm retained in connection with the

CFO search process and will direct such firm to fully cooperate with the Agents

and CBW regarding all reasonable requests for information or documentation in

connection therewith.  The Borrowers

will continue to work in good faith with the Agents and their professionals to

refine the description of the required qualifications, capabilities, role and

authority of the CFO position.

(r)            Severance Agreements.  The Borrowers shall not enter into any

severance agreement (a “Severance Agreement”) with, or similar

arrangement providing for the payment of money or other consideration (a “Severance

Payment”) to, any current or former employee in connection with the

termination (under any circumstances) of such employee’s employment with a

Borrower without the Agents’ prior written consent, which shall not be

unreasonably withheld or delayed, provided that a Borrower may enter into

a Severance and Release Agreement (a “Release”) which is contemplated by

and executed in connection with a Severance Agreement existing on the date

hereof, so long as such Release does not expand the rights of any employee

under the related Severance Agreement. 

The Borrowers will promptly deliver to the Agents copies of all Releases

reasonably requested by the Agents or CBW and will not make any Severance

Payments or enter into any Release without first providing 5 Business

Days’ prior written notice to the Agents. 

The Borrowers will not make any discretionary non-contractual Severance

Payments without the Agents’ prior written consent.

(s)           Net Disposition Proceeds.  The Borrowers agree that notwithstanding

anything to the contrary contained in the second sentence of the definition of

“Net Disposition Proceeds” in the Credit Agreement, Net Disposition Proceeds

shall exclude only an aggregate amount equal to $500,000 of proceeds of

Permitted Dispositions received on or after July 1, 2001 through and until

the termination of the Forbearance Period, provided that the proceeds of

(i) any Permitted Disposition resulting in proceeds of less than $50,000 and

(ii) the sale of Obsolete Inventory (as defined below), shall also be

excluded from Net Disposition Proceeds and shall not be counted toward the

$500,000 basket.  “Obsolete Inventory”

shall mean inventory for which the U.S. Borrower took an inventory reserve for

Fiscal Year 2001 or which comprises part of a discontinued product line, other

than inventory transferred in connection with a sale of all of the stock, all

or substantially all of the assets, or a division or other similar operating or

administrative unit of a Borrower or a Subsidiary or Affiliate of a

Borrower.  As part of the second weekly

rolling cash flow forecast for any month, the U.S. Borrower shall deliver to

the Agents, with respect to the prior month, a report certified by David Coles,

of the sales value, standard cost and inventory reserve associated with the

Obsolete Inventory sold in such month.

(t)            Continued Compliance with Loan Documents.  Each of the Borrowers will continue to

comply with all of its covenants and other obligations under the Credit

Agreement and the other Loan Documents.

The provisions contained in paragraphs (a), (c),

(d), (f), (i), (o), (r) and (s) above shall continue to and including the date

of termination of the Forbearance Period (and shall terminate on such date) and

the provisions contained in paragraphs (b), (e), (g), (h), (j), (k), (l),

(m), (n), (p), (q) and (t) shall survive termination of the Forbearance

Period.  Nothing in this Agreement,

including paragraph 4(s) or the termination thereof, shall prejudice or

otherwise affect the right of any party to argue that the sale of Obsolete

Inventory by a Borrower does or does not constitute a Permitted Disposition or

that the proceeds of any such sale do or do not constitute Net Disposition

Proceeds, and no party shall assert in any proceeding or other context that

terms of paragraph 4(s) or the termination thereof are relevant to any

such argument.

Section

5.  Consent to Payment of Fees and

Expenses of Professionals Engaged by the Subordinated Note Holders. 

(a) Financial Consultants. 

The Agents and the Required Lenders hereby consent to the U.S.

Borrower’s payment to Chanin Capital Partners LLC (“Chanin”), financial

consultants to certain Subordinated Note Holders, of a monthly fee of $125,000,

up to an aggregate of $250,000 and a “Deferred Fee” of up to $500,000, provided

that prior to any such payments the Agents shall have approved the form and

substance of an engagement letter to be executed by the U.S. Borrower and

Chanin and (ii) at least $250,000 of the “Deferred Fee” shall be paid

exclusively out of the proceeds of an equity investment made by a third party

in the U.S. Borrower.

(b)           Attorneys.  The Agents and the Required Lenders hereby consent to the U.S.

Borrower’s payment to Dewey Ballantine LLP, counsel to certain Subordinated

Note Holders, of a retainer of $75,000 and to the U.S. Borrower’s payment of

reasonable fees and expenses of Dewey Ballantine, LLP; provided, that

prior to any such payments the Agents shall have approved the form and

substance of an engagement letter to be executed by the U.S. Borrower and Dewey

Ballantine LLP.

Section

6.  Effect and Construction of

Agreement.  Except as expressly provided herein, the

Credit Agreement and the other Loan Documents shall remain in full force and

effect in accordance with their respective terms, and this Agreement shall not

be construed to:

(a)           impair

the validity, perfection or priority of any Lien or security interest securing

the Obligations;

(b)           waive

or impair any rights, powers or remedies of any Agent or any Lender under the

Credit Agreement or any other Loan Document upon termination of the Forbearance

Period, with respect to the Existing Defaults or otherwise;

(c)           constitute

an agreement by any Agent or any Lender or to require any Agent or any Lender

to extend the Forbearance Period, or grant additional forbearance periods, or

extend the term of the Credit Agreement or the time for payment of any of the

Obligations; or

(d)           require

any Lender to make any Loans or other extensions of credit to the Borrower.

In the event of any inconsistency between the terms of

this Agreement and the Credit Agreement or any of the other Loan Documents,

this Agreement shall govern.  The

Borrowers acknowledge that they have consulted with counsel and with such other

experts and advisors as they have deemed necessary in connection with the

negotiation, execution and delivery of this Agreement.  This Agreement shall be construed without

regard to any presumption or rule requiring that it be construed against the

party causing this Agreement or any part hereof to be drafted.

Section

7.  Reference to and Effect on the

Loan Documents.

(a)           Upon

the effectiveness hereof, each reference in the Credit Agreement to “this

Agreement,” “hereunder,” “hereof” or words of like import referring to the

Credit Agreement, and each reference in the other Loan Documents to the Credit

Agreement, “thereunder,” “thereof” or words of like import referring to the

Credit Agreement, shall mean and be a reference to the Credit Agreement, as

amended hereby.

(b)           This

Agreement shall be a Loan Document.

Section

8.  Miscellaneous.

(a)           Further Assurances.  The Borrowers agree to execute such other

and further documents and instruments as the Agents may request to implement

the provisions of this Agreement.

(b)           Benefit of Agreement.  This Agreement shall be binding upon and

inure to the benefit of and be enforceable by the parties hereto and their

respective successors and assigns.  No

other person or entity shall be entitled to claim any right or benefit

hereunder, including, without limitation, the status of a third-party

beneficiary of this Agreement.

(c)           Integration.  This Agreement, together with the Credit Agreement and the other

Loan Documents, constitutes the entire agreement and understanding among the

parties relating to the subject matter hereof, and supersedes all prior

proposals, negotiations, agreements and understandings relating to such subject

matter.  In entering into this

Agreement, the Borrowers acknowledge that they are relying on no statement,

representation, warranty, covenant or agreement of any kind made by any Agent,

any Lender or any employee or agent of any Agent or any Lender, except for the

agreements of the Agents and the Lenders set forth herein.

(d)           Severability.  The provisions of this Agreement are intended to be

severable.  If any provision of this

Agreement shall be held invalid or unenforceable in whole or in part in any

jurisdiction, such provision shall, as to such jurisdiction, be ineffective to

the extent of such invalidity or enforceability without in any manner affecting

the validity or enforceability of such provision in any other jurisdiction or

the remaining provisions of this Agreement in any jurisdiction.

(e)           Counterparts; Telecopied Signatures.  This Agreement may be executed in any number

of counterparts and by different parties to this Agreement on separate

counterparts, each of which, when so executed, shall be deemed an original, but

all such counterparts shall constitute one and the same agreement.  Any signature delivered by a party by

facsimile transmission shall be deemed to be, and effective as, an original

signature hereto.

(f)            Notices.  Any notices with respect to this Agreement shall be given in the

manner provided for in Section 12.2 of the Credit Agreement.

(g)           Survival.  Except as otherwise provided herein, all representations, warranties,

covenants, agreements, undertakings, waivers and releases of the Borrowers

contained herein shall survive the termination of the Forbearance Period.

(h)           Amendment.  No amendment, modification, rescission, waiver or release of any

provision of this Agreement shall be effective unless the same shall be in

writing and signed by the Borrowers, the Agents and the Required Lenders.

Section

9.  RELEASE OF CLAIMS. 

EACH OF THE BORROWERS HEREBY ACKNOWLEDGES AND AGREES THAT IT DOES NOT

HAVE ANY DEFENSES, COUNTERCLAIMS, OFFSETS, CROSS-CLAIMS, CLAIMS OR DEMANDS OF

ANY KIND OR NATURE WHATSOEVER THAT CAN BE ASSERTED TO REDUCE OR ELIMINATE ALL

OR ANY PART OF THE LIABILITY OF THE BORROWERS TO REPAY ANY AGENT OR ANY LENDER

AS PROVIDED IN THE CREDIT AGREEMENT AND THE OTHER LOAN DOCUMENTS OR TO SEEK

AFFIRMATIVE RELIEF OR DAMAGES OF ANY KIND OR NATURE FROM ANY AGENT OR ANY

LENDER.  EACH OF THE BORROWERS HEREBY

VOLUNTARILY AND KNOWINGLY RELEASES AND FOREVER DISCHARGES THE AGENTS AND THE

LENDERS, AND EACH AGENT’S AND LENDER’S PREDECESSORS, AGENTS, EMPLOYEES,

CONSULTANTS, ADVISORS, ATTORNEYS, SUCCESSORS AND ASSIGNS, FROM ALL POSSIBLE

CLAIMS, DEMANDS, ACTIONS, CAUSES OF ACTION, DAMAGES, COSTS, EXPENSES, AND

LIABILITIES WHATSOEVER, KNOWN OR UNKNOWN, ANTICIPATED OR UNANTICIPATED,

SUSPECTED OR UNSUSPECTED, FIXED, CONTINGENT, OR CONDITIONAL, AT LAW OR IN

EQUITY, ORIGINATING IN WHOLE OR IN PART ON OR BEFORE THE DATE THIS AGREEMENT IS

EXECUTED, WHICH THE BORROWERS MAY NOW OR HEREAFTER HAVE AGAINST ANY SUCH AGENT

OR LENDER, AND SUCH AGENT’S OR LENDER’S PREDECESSORS, AGENTS, EMPLOYEES,

CONSULTANTS, ADVISORS, ATTORNEYS, SUCCESSORS AND ASSIGNS, IF ANY, AND

IRRESPECTIVE OF WHETHER ANY SUCH CLAIMS ARISE OUT OF CONTRACT, TORT, VIOLATION

OF LAW OR REGULATIONS, OR OTHERWISE, INCLUDING, WITHOUT LIMITATION, THE

EXERCISE OF ANY RIGHTS AND REMEDIES UNDER THE CREDIT AGREEMENT OR OTHER LOAN

DOCUMENTS, AND NEGOTIATION AND EXECUTION OF THIS AGREEMENT.

Each of the Borrowers acknowledges and agrees that it

understands the meaning and effect of Section 1542 of the California Civil Code

which provides:

“A general release does not extend to claims which the creditor does

not know or suspect to exist in his favor at the time of executing the release,

which if known by him must have materially affected his settlement with the

debtor.”

EACH OF THE BORROWERS AGREES TO ASSUME THE RISK OF ANY

AND ALL UNKNOWN, UNANTICIPATED OR MISUNDERSTOOD DEFENSES, CLAIMS, CONTRACTS,

LIABILITIES, INDEBTEDNESS AND OBLIGATIONS WHICH ARE RELEASED, WAIVED AND

DISCHARGED BY THIS AGREEMENT.  EACH OF

THE BORROWERS HEREBY WAIVES AND RELINQUISHES ALL RIGHTS AND BENEFITS WHICH IT

MIGHT OTHERWISE HAVE UNDER THE AFOREMENTIONED SECTION 1542 OF THE CALIFORNIA

CIVIL CODE OR ANY SIMILAR LAW, TO THE EXTENT SUCH LAW MAY BE APPLICABLE, WITH

REGARD TO THE RELEASE OF SUCH UNKNOWN, UNANTICIPATED OR MISUNDERSTOOD DEFENSES,

CLAIMS, CONTRACTS, LIABILITIES, INDEBTEDNESS AND OBLIGATIONS.  TO THE EXTENT THAT SUCH LAWS MAY BE

APPLICABLE, EACH OF THE BORROWERS WAIVES AND RELEASES ANY RIGHT OR DEFENSE

WHICH IT MIGHT OTHERWISE HAVE UNDER ANY OTHER LAW OF ANY APPLICABLE

JURISDICTION WHICH MIGHT LIMIT OR RESTRICT THE EFFECTIVENESS OR SCOPE OF ANY OF

THEIR WAIVERS OR RELEASES HEREUNDER.

Section

10.  GOVERNING LAW; JURISDICTION;

WAIVER OF JURY TRIAL.  THIS AGREEMENT SHALL BE

GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE INTERNAL LAWS OF THE STATE

OF NEW YORK.  THE JURISDICTIONAL, VENUE

AND SERVICE OF PROCESS PROVISIONS IN SECTION 12.14 OF THE CREDIT AGREEMENT

AND THE JURY TRIAL WAIVER IN SECTION 12.15 OF THE CREDIT AGREEMENT SHALL

APPLY TO ANY SUIT, ACTION OR PROCEEDING RELATED TO THIS AGREEMENT.

IN

WITNESS WHEREOF,

the parties hereto have executed this Agreement as of the date first above

written.

	

   

  	

  LEINER HEALTH PRODUCTS INC.

  
	

   

  	

  By:

  	

   

  
	

   

  	

   

  	

  Name: 

  Title: 

  
	

   

  	

  VITA HEALTH PRODUCTS INC.

  
	

   

  	

  By:

  	

   

  
	

   

  	

   

  	

  Name:

  Title:

  

 

AGREED TO AND ACCEPTED

AS OF THE DATE FIRST

ABOVE WRITTEN:

THE BANK OF NOVA SCOTIA

As Canadian Agent and a Lender

 

	

  By:

  	

   

  	

   

  
	

   

  	

  Name:
 Title:

  	

   

  

AGREED TO AND ACCEPTED

AS OF THE DATE FIRST 

ABOVE WRITTEN:

THE BANK OF NOVA SCOTIA,

as the U.S. Agent and a Lender

 

	

  By:

  	

   

  	

   

  
	

   

  	

  Name:

  Title:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00030-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00030-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00030-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00030-of-00352.parquet"}]]